DiaSorin (DIA.MI) stock price, revenue, and financials

DiaSorin market cap is €10 b, and annual revenue was €881.31 m in FY 2020

€10 B

DIA.MI Mkt cap, 10-Nov-2021

€515.4 M

DiaSorin Revenue H1, 2021
DiaSorin Gross profit (H1, 2021)355.3 M
DiaSorin Gross profit margin (H1, 2021), %68.9%
DiaSorin Net income (H1, 2021)150 M
DiaSorin EBIT (H1, 2021)201.9 M
DiaSorin Cash, 30-Jun-2021896.8 M
DiaSorin EV9.6 B
Get notified regarding key financial metrics and revenue changes at DiaSorinLearn more
Banner background

DiaSorin Revenue

DiaSorin revenue was €881.31 m in FY, 2020 which is a 24.8% year over year increase from the previous period.

Embed Graph

DiaSorin Revenue Breakdown

Embed Graph

DiaSorin revenue breakdown by geographic segment: 44.4% from Europe and Africa, 40.5% from USA and Canada, 11.4% from Asia Pacific and 3.6% from Other

DiaSorin Income Statement

Annual

EURFY, 2018FY, 2019FY, 2020

Revenue

669.2m706.3m881.3m

Revenue growth, %

6%25%

Cost of goods sold

213.4m217.6m278.4m

Gross profit

455.8m488.7m602.9m

Gross profit Margin, %

68%69%68%

Sales and marketing expense

133.1m142.8m144.1m

R&D expense

45.1m47.9m50.8m

General and administrative expense

67.2m69.6m72.1m

Operating expense total

251.2m270.8m278.7m

EBIT

204.5m217.9m324.2m

EBIT margin, %

31%31%37%

Pre tax profit

204.4m216.3m321.4m

Income tax expense

46.2m40.6m73.1m

Net Income

158.1m175.7m248.3m

EPS

2.93.24.5

Half Year

EURH1, 2019H1, 2020H1, 2021

Revenue

350.3m382.3m515.4m

Cost of goods sold

107.0m118.2m160.1m

Gross profit

243.3m264.1m355.3m

Gross profit Margin, %

69%69%69%

Sales and marketing expense

70.4m70.9m74.7m

R&D expense

23.3m25.5m23.5m

General and administrative expense

34.3m34.8m37.9m

Operating expense total

133.1m140.4m153.5m

EBIT

110.2m123.6m201.9m

EBIT margin, %

31%32%39%

Pre tax profit

109.1m122.2m196.1m

Income tax expense

25.1m27.5m46.1m

Net Income

84.0m94.7m150.0m

EPS

1.51.72.6

DiaSorin Balance Sheet

Annual

EURFY, 2018FY, 2019FY, 2020

Cash

73.1m157.6m339.9m

Accounts Receivable

131.1m132.5m165.7m

Inventories

160.4m171.1m191.2m

Current Assets

414.9m530.8m713.9m

PP&E

95.0m128.4m140.5m

Goodwill

162.6m164.7m154.8m

Total Assets

905.9m1.1b1.2b

Accounts Payable

57.3m55.7m65.5m

Short-term debt

20.6m4.8m4.2m

Current Liabilities

138.5m122.5m160.2m

Long-term debt

81.0k24.5m30.5m

Non-Current Liabilities

62.8m92.5m129.9m

Total Debt

20.7m29.3m34.7m

Total Liabilities

201.2m214.9m290.1m

Common Stock

55.9m55.9m55.9m

Additional Paid-in Capital

18.2m18.2m18.2m

Retained Earnings

453.8m571.7m670.9m

Total Equity

704.7m848.6m956.3m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.3 x1.3 x1.3 x

Half Year

EURH1, 2019H1, 2020H1, 2021

Cash

90.1m138.7m896.8m

Accounts Receivable

136.3m158.2m158.4m

Inventories

167.5m195.3m203.0m

Current Assets

461.4m595.8m1.3b

PP&E

125.3m126.4m159.7m

Goodwill

163.4m164.3m158.1m

Total Assets

987.7m1.1b1.9b

Accounts Payable

52.1m61.9m79.2m

Short-term debt

47.2m4.0m5.4m

Current Liabilities

154.9m152.4m154.6m

Long-term debt

24.9m22.9m463.7m

Non-Current Liabilities

85.6m94.3m567.7m

Total Debt

72.0m27.0m469.1m

Total Liabilities

240.5m246.7m722.3m

Common Stock

55.9m55.9m55.9m

Additional Paid-in Capital

18.2m18.2m18.2m

Retained Earnings

566.7m692.5m860.1m

Total Equity

747.2m887.0m1.1b

Debt to Equity Ratio

0.1 x0 x0.4 x

Debt to Assets Ratio

0.1 x0 x0.3 x

Financial Leverage

1.3 x1.3 x1.6 x

DiaSorin Cash Flow

Annual

EURFY, 2018FY, 2019FY, 2020

Net Income

158.1m175.7m248.3m

Depreciation and Amortization

50.8m59.0m61.0m

Accounts Receivable

(637.0k)(51.0k)(39.0m)

Inventories

(14.4m)(9.8m)(30.2m)

Accounts Payable

(8.6m)(1.8m)11.0m

Cash From Operating Activities

209.9m232.7m304.6m

Purchases of PP&E

(33.2m)(37.4m)(42.5m)

Cash From Investing Activities

(71.4m)(59.1m)(73.0m)

Long-term Borrowings

(13.6m)(47.3m)(7.5m)

Dividends Paid

(145.3m)(49.2m)(52.1m)

Cash From Financing Activities

(224.2m)(89.5m)(40.9m)

Net Change in Cash

(86.2m)84.4m182.3m

Income Taxes Paid

25.8m(42.6m)(36.9m)

Half Year

EURH1, 2019H1, 2020H1, 2021

Net Income

84.0m94.7m150.0m

Depreciation and Amortization

29.1m30.0m29.5m

Accounts Receivable

(4.5m)(28.7m)8.2m

Inventories

(7.3m)(29.4m)(20.0m)

Accounts Payable

(5.3m)6.5m13.4m

Cash From Operating Activities

92.7m105.4m173.7m

Purchases of PP&E

(16.6m)(19.7m)(29.8m)

Cash From Investing Activities

(28.7m)(31.4m)(49.6m)

Long-term Borrowings

(20.4m)(36.7m)

Dividends Paid

(49.2m)(52.0m)(54.0m)

Cash From Financing Activities

(47.7m)(91.6m)429.3m

Net Change in Cash

17.0m(18.8m)557.0m

Income Taxes Paid

(20.6m)5.0m(66.1m)

DiaSorin Ratios

EURFY, 2018

Revenue/Employee

339.5k

Financial Leverage

1.3 x

DiaSorin Operating Metrics

FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020FY, 2020Q1, 2021Q2, 2021

Countries

24

Countries (Distributors)

93

Distributors

200200

Manufacturing Facilities

766

Manufacturing Sites

12145

New Placements (Liaison XL)

11612412611315294241416598183299

Overall Installed Base (Liaison XL)

7.85 k7.95 k8.06 k8.16 k8.29 k8.38 k8.53 k8.6 k8.78 k8.94 k9.03 k

Projects (Immune and Molecular)

81828

Projects (Reagents for Immunoassay)

202817

Projects (Reagents for Molecular)

342222

R&D Facilities

555

DiaSorin Human Capital

DiaSorin's employees are reported to be approximately 45% female and 55% male.

Job Roles

FY, 2020FY, 2019FY, 2018
Executives5.6%5.5%
Blue Collars17.9%15%14.6%
White Collars76.5%79.6%80.5%
Other4.9%
FY, 2020FY, 2019FY, 2018
Male55.2%54.8%63.9%
Female44.8%45.2%36.1%

DiaSorin Employee Rating

3.7114 votes
Culture & Values
3.2
Work/Life Balance
3.3
Senior Management
3.1
Salary & Benefits
3.7
Career Opportunities
3.2
Source